Alprolix pediatric data?

Here’s a concise summary of pediatric data for Alprolix (eftrenonacog alfa):

- What it covers
- Pediatric patients with hemophilia B (factor IX deficiency) for routine prophylaxis and treatment of bleeds. Data available for children and adolescents up to 17 years old in US/EU labeling.

- Efficacy (in kids)
- Prophylaxis in pediatric patients reduces annual bleed rates and provides protection comparable to adults when dosing is individualized.
- Bleed control during on-demand treatment is supported in pediatric studies as well.

- Pharmacokinetics
- Alprolix has an extended half-life due to the Fc fusion; pediatric pharmacokinetics have been studied and used to guide weight-based dosing.
- Dosing intervals can be extended (up to about every 14 days) in carefully selected pediatric patients with stable trough levels, similar to adults, but dosing is individualized.

- Safety
- Overall safety profile in children mirrors adults: common AEs include injection site reactions, headache, nasopharyngitis; inhibitors to FIX are rare in pediatric populations.
- Monitoring for safety issues and trough levels is recommended per the label.

- Dosing considerations (high level)
- Dosing is weight-based and individualized to maintain adequate trough FIX activity.
- In pediatrics, clinicians may adjust dose and interval based on bleeding phenotype, activity level, and trough levels.

If you’d like, I can pull the exact pediatric study details (ages included, trial names like B-LONG/Kids B-LONG, sample sizes, specific efficacy endpoints, and the labeled dosing tables). Tell me whether you want:
- a quick summary for a clinician,
- or the exact references and numbers from the label/trials, and the patient’s age range you have in mind.